BioWorld Asia

Feb. 21, 2007

Bavarian Nordic Raising $82M In Discounted Rights Offering

Bavarian Nordic A/S is set to raise gross proceeds of DKK465 million (US$82 million) from a fully underwritten rights issue directed at current shareholders. (BioWorld International) Read More

Ark Gets OKs To Advance Vitor Into Phase III Studies

Receptor May Hold Key To Treating Myeloma

Basilea Pharma Hits New High On Alitretinoin Phase III Data

Celogos Licenses Myoblast Tool For Stress Urinary Incontinence

Other News To Note

CeNeS Pain Compound Shows Good Results, With One Glitch

New French Biosimilar Controls Get Warm Welcome In Europe

EU Launches Study To Boost Biotech Competitiveness

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...